Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET.

Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Individuals interested in listening to the conference call may do so by dialing [phone] for U.S callers and [phone] for other locations and reference conference ID 643827, or from the webcast link in the investor relations section of the company's website at: www.revance.com.

A webcast replay will be available beginning February 28, 2024, at 4.30 p.m. PT / 7.30 p.m. ET to May 28, 2024, at 4.30 p.m. PT / 7.30 p.m. ET. To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (daxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DaxxifyTherapy.com, or connect with us on LinkedIn.

“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221311035/en/

Investors Revance Therapeutics, Inc.: Jessica Serra, 510-279-6886 [e-mail]

or

Gilmartin Group, LLC.: Laurence Watts, 619-916-7620 [e-mail]

Media Revance Therapeutics, Inc.: Cathryn Castaldo, 615-245-7567 [e-mail]